NRX Pharmaceuticals IncNASDAQ:NRXPNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.5400
- TODAY'S CHANGE (%)0.0100 (0.6536%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close1.5500 / 1.5300
- Day Range
- 52 Week Range
- Volume60,883
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NRXP |
|---|---|---|
| 09:32 ET | 963 | 1.57 |
| 09:39 ET | 500 | 1.53 |
| 09:54 ET | 1449 | 1.5497 |
| 09:56 ET | 200 | 1.55 |
| 09:59 ET | 100 | 1.5387 |
| 10:06 ET | 2372 | 1.5301 |
| 10:08 ET | 1205 | 1.52 |
| 10:10 ET | 2305 | 1.5069 |
| 10:19 ET | 500 | 1.51 |
| 10:21 ET | 1500 | 1.5199 |
| 10:42 ET | 10831 | 1.5 |
| 10:50 ET | 1905 | 1.5 |
| 11:04 ET | 186 | 1.5 |
| 11:06 ET | 100 | 1.5 |
| 11:20 ET | 2000 | 1.5099 |
| 11:26 ET | 888 | 1.5099 |
| 11:29 ET | 1000 | 1.51 |
| 11:31 ET | 600 | 1.518 |
| 11:33 ET | 132 | 1.5115 |
| 11:44 ET | 100 | 1.5108 |
| 11:49 ET | 570 | 1.51 |
| 12:12 ET | 345 | 1.52 |
| 12:14 ET | 1000 | 1.52 |
| 12:16 ET | 300 | 1.53 |
| 12:27 ET | 2074 | 1.53 |
| 12:43 ET | 5484 | 1.53 |
| 12:48 ET | 500 | 1.511 |
| 01:08 ET | 650 | 1.53 |
| 01:39 ET | 200 | 1.54 |
| 02:13 ET | 100 | 1.51 |
| 02:18 ET | 500 | 1.525 |
| 02:24 ET | 100 | 1.5352 |
| 02:29 ET | 100 | 1.54 |
| 02:44 ET | 100 | 1.52 |
| 03:05 ET | 100 | 1.54 |
| 03:09 ET | 2500 | 1.535 |
| 03:14 ET | 100 | 1.53 |
| 03:16 ET | 300 | 1.54 |
| 03:23 ET | 100 | 1.535 |
| 03:34 ET | 100 | 1.53 |
| 03:48 ET | 100 | 1.53 |
| 03:50 ET | 100 | 1.5302 |
| 03:52 ET | 2600 | 1.5302 |
| 03:54 ET | 100 | 1.52 |
| 03:56 ET | 200 | 1.53 |
| 03:57 ET | 7550 | 1.535 |
| 03:59 ET | 1529 | 1.54 |
Oct 3, 2024
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic, from 6:55AM ET on Thursday Oct 03, 2024 by Dow Jones
6:55AM ET on Thursday Oct 03, 2024 by Dow Jones*DJ HOPE Therapeutics, Inc. And NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing Of A Letter Of Intent To Acquire A Premier West Coast Interventional Psychiatric Clinic >NRXP, from 6:55AM ET on Thursday Oct 03, 2024 by Dow Jones
6:55AM ET on Thursday Oct 03, 2024 by Dow Jones
Sep 30, 2024
Sep 12, 2024
DJ NRX Pharmaceuticals Is Maintained at Buy by Ascendiant Capital, from 2:08PM ET on Thursday Sep 12, 2024 by Dow Jones
2:08PM ET on Thursday Sep 12, 2024 by Dow Jones
Sep 11, 2024
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com, from 7:55AM ET on Wednesday Sep 11, 2024 by Dow Jones
7:55AM ET on Wednesday Sep 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NRX Pharmaceuticals Inc | 16.6M | -1.0x | --- |
Biomx Inc | 16.4M | -2.0x | --- |
Athira Pharma Inc | 16.3M | -0.1x | --- |
Monopar Therapeutics Inc | 16.2M | -2.0x | --- |
Mira Pharmaceuticals Inc | 17.0M | -1.3x | --- |
Kairos Pharma Ltd | 17.0M | -8.5x | --- |
Company Information
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Contact Information
- Headquarters
- 1201 ORANGE STREET, SUITE 600WILMINGTON, DE, United States 19801
- Phone
- 484-254-6134
- Fax
- 302-575-1642
Executives
- Chairman of the Board, Chief Scientific Officer
- Jonathan Javitt
- Chief Executive Officer, Director
- Stephen Willard
- Interim Chief Financial Officer
- Richard Narido
- CMC and Technical Operations Advisor
- Riccardo Panicucci
- Independent Director
- Patrick Flynn
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-1.62 |
Book Value | $-0.14 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
